181 related articles for article (PubMed ID: 36095848)
1. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
Ho TC; Maamari RN; Kossler AL; Sears CM; Freitag SK; Reshef ER; Shinder R; Rootman DB; Diniz SB; Kahana A; Schlachter D; Do TH; Kally P; Turner S; Mokhtarzadeh A; Harrison AR; Hwang CJ; Kim HJ; Avila SA; Thomas DA; Magazin M; Wester ST; Lee WW; Clauss KD; Holds JB; Sniegowski M; Compton CJ; Briggs C; Malik AI; Lucarelli MJ; Burkat CN; Patel LG; Couch SM
Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):150-155. PubMed ID: 36095848
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for chronic thyroid eye disease.
Ozzello DJ; Dallalzadeh LO; Liu CY
Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
8. Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population.
Diniz SB; Cohen LM; Roelofs KA; Rootman DB
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):583-591. PubMed ID: 33710036
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
Tamhankar MA; Pradeep T; Chen Y; Briceño CA
J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
[TBL] [Abstract][Full Text] [Related]
11. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
Hwang CJ; Rebollo NP; Mechels KB; Perry JD
Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease.
Hubschman S; Sojitra B; Ghiam S; Sears C; Hwangbo N; Goldberg RA; Rootman DB
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):270-275. PubMed ID: 37972968
[TBL] [Abstract][Full Text] [Related]
13. Echographic Assessment of Extraocular Muscle Response to Teprotumumab.
Tran C; Pham CM; Simmons BA; Warner LL; Fuhrmeister LJ; Shriver EM
Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):336-339. PubMed ID: 34652310
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab for thyroid eye disease: early response is not required for benefit.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS
Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
16. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease.
Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO
Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
18. Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease.
Reshef ER; Marsiglia M; Bouhadjer K; Chiou CA; O'Brien-Coon D; Reinshagen KL; Freitag SK
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):433-439. PubMed ID: 36852831
[TBL] [Abstract][Full Text] [Related]
19. Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.
Lin F; Yao Q; Yu B; Deng Z; Qiu J; He R
Int J Clin Pract; 2023; 2023():6638089. PubMed ID: 37588100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
